Bouvin-Pley, M. and Morgand, M. and Meyer, L. and Goujard, C. and Moreau, A. and Mouquet, H. and Nussenzweig, M. and Pace, C. and Ho, D. and Bjorkman, P. J. and Baty, D. and Chames, P. and Pancera, M. and Kwong, P. D. and Poignard, P. and Barin, F. and Braibant, M. (2014) Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. Journal of Virology, 88 (23). pp. 13910-13917. ISSN 0022-538X. PMCID PMC4248973. doi:10.1128/JVI.02083-14. https://resolver.caltech.edu/CaltechAUTHORS:20141001-132423634
|
PDF
- Published Version
See Usage Policy. 576kB |
Use this Persistent URL to link to this item: https://resolver.caltech.edu/CaltechAUTHORS:20141001-132423634
Abstract
Extending our previous analyses to the most recently described broadly neutralizing monoclonal antibodies (bNAbs) we confirm a drift of HIV-1 clade B variants over two decades toward higher resistance to bNAbs targeting almost all the identified gp120 neutralizing epitopes. In contrast, the sensitivity to bNAbs targeting the gp41 MPER remained stable, suggesting a selective pressure on gp120 preferentially. Despite this evolution, selected combinations of bNAbs remain capable to neutralize efficiently most of the circulating variants.
| Item Type: | Article | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related URLs: |
| ||||||||||||
| ORCID: |
| ||||||||||||
| Additional Information: | © 2014 American Society for Microbiology. Received 16 July 2014. Accepted 9 September 2014. Published ahead of print 17 September 2014. This work was supported by the Agence Nationale de Recherches sur le SIDA et les hépatites (ANRS, Paris, France) and in part by the Intramural program of the Vaccine Research Center, NIAID/NIH. Mélanie Bouvin-Pley was supported by doctoral fellowships from the Région Centre and Sidaction (France). Marion Morgand was supported by a doctoral fellowship from the ANRS. We thank the patients and clinicians who participated in the ANRS SEROCO CO2 and PRIMO CO6 cohorts. The following reagents were obtained through the NIH AIDS Research and Reference Reagent program, Division of AIDS, NIAID, NIH: pNL4.3.LUC.R-E- from Nathaniel Landau; TZM-bl cells from John C. Kappes, Xiaoyun Wu, and Tranzyme Inc.; HIV-1 anti-gp41 mAb (10E8), from Dr. Mark Connors. | ||||||||||||
| Funders: |
| ||||||||||||
| Issue or Number: | 23 | ||||||||||||
| PubMed Central ID: | PMC4248973 | ||||||||||||
| DOI: | 10.1128/JVI.02083-14 | ||||||||||||
| Record Number: | CaltechAUTHORS:20141001-132423634 | ||||||||||||
| Persistent URL: | https://resolver.caltech.edu/CaltechAUTHORS:20141001-132423634 | ||||||||||||
| Official Citation: | Drift of the HIV-1 Envelope Glycoprotein gp120 toward Increased Neutralization Resistance over the Course of the Epidemic: a Comprehensive Study Using the Most Potent and Broadly Neutralizing Monoclonal Antibodies M. Bouvin-Pley, M. Morgand, L. Meyer, C. Goujard, A. Moreau, H. Mouquet, M. Nussenzweig, C. Pace, D. Ho, P. J. Bjorkman, D. Baty, P. Chames, M. Pancera, P. D. Kwong, P. Poignard, F. Barin, and M. Braibant J. Virol. December 2014 88:23 13910-13917; Accepted manuscript posted online 17 September 2014, doi:10.1128/JVI.02083-14 | ||||||||||||
| Usage Policy: | No commercial reproduction, distribution, display or performance rights in this work are provided. | ||||||||||||
| ID Code: | 50149 | ||||||||||||
| Collection: | CaltechAUTHORS | ||||||||||||
| Deposited By: | Ruth Sustaita | ||||||||||||
| Deposited On: | 02 Oct 2014 20:53 | ||||||||||||
| Last Modified: | 10 Nov 2021 18:52 |
Repository Staff Only: item control page
